Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations

Research output: Contribution to journalReviewResearchpeer-review

  1. Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of somatic hospitalization in parents after cancer in a child, a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Socioeconomic position and maintenance therapy in children with acute lymphoblastic leukemia: A national cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with nucleotide synthesis and salvage pathways. The primary cytotoxic mechanism involves the incorporation of thioguanine nucleotides (TGNs) into DNA (as DNA-TG), which may be enhanced by the inhibition of de novo purine synthesis by other MTX/6-MP metabolites. Co-medication during MT is common. Although Pneumocystis jirovecii prophylaxis appears safe, the benefit of glucocorticosteroid/vincristine pulses in improving survival and of allopurinol to moderate 6-MP pharmacokinetics remains uncertain. Numerous genetic polymorphisms influence the pharmacology, efficacy, and toxicity (mainly myelosuppression and hepatotoxicity) of MTX and thiopurines. Thiopurine S-methyltransferase (encoded by TPMT) decreases TGNs but increases methylated 6-MP metabolites (MeMPs); similarly, nudix hydrolase 15 (encoded by NUDT15) also decreases TGNs available for DNA incorporation. Loss-of-function variants in both genes are currently used to guide MT, but do not fully explain the inter-patient variability in thiopurine toxicity. Because of the large inter-individual variations in MTX/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy-the addition of low-dose (2.5-12.5 mg/m2/day) 6-thioguanine to the 6-MP/MTX backbone-that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk.

Original languageEnglish
JournalLeukemia
Volume36
Issue number7
Pages (from-to)1749-1758
Number of pages10
ISSN0887-6924
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

© 2022. The Author(s).

    Research areas

  • Humans, Mercaptopurine, Methotrexate/therapeutic use, Methyltransferases/genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Recurrence, Thioguanine/therapeutic use

ID: 79118473